Pulmonary Hypertension in Children - a Practical Approach

Area of Science:

• Cardiology
• Pulmonology
• Vascular Medicine

Background:

• Pulmonary hypertension (PH) is defined as mean pulmonary arterial pressure > 25 mmHg at rest.
• While rare overall, PH prevalence is elevated in specific groups, reaching 30% in congenital heart disease (CHD) patients.
• Early vascular changes in PH associated with CHD can be reversible, but progression may occur despite corrective surgery.

Purpose of the Study:

• To define the clinical significance of the "gray area" in operable vs. inoperable CHD with PH.
• To highlight the importance of pulmonary vasoreactivity testing in this specific patient subgroup.
• To underscore the severe morbidity and mortality associated with untreated or advanced pulmonary hypertension.

Main Methods:

• Cardiac catheterization to measure pulmonary vascular resistance (PVR) and PVR to systemic vascular resistance ratio.
• Identification of a "gray area" defined by PVR of 4-8 WU/m and a PVR/SVR ratio of 0.3-0.5.
• Indication of pulmonary vasoreactivity testing for patients within this "gray area".

Main Results:

• The "gray area" represents an intermediate group of CHD patients with PH.
• This subgroup requires further assessment via pulmonary vasoreactivity testing.
• Pulmonary hypertension significantly increases the risk of decreased cardiac output and heart failure.

Conclusions:

• Accurate hemodynamic assessment is vital for managing PH in CHD.
• Pulmonary vasoreactivity testing is indicated for CHD patients with intermediate PVR and PVR/SVR ratios.
• Timely intervention is critical to mitigate the severe consequences of pulmonary hypertension.